Filing Flows › Glaukos (GKOS) › Stock forecast & fair value
Glaukos (GKOS) stock forecast and fair value
Glaukos (GKOS) trades at $181.43. 13 analysts' median price target is $241.00 (+33%), from $225.00 to $270.00. Across 16 valuation methods the middle fair value is $40.00 (-78%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $27.20 | $39.22 | $62.16 | -78% |
| EV/Sales vs peers, weighted | $31.33 | $47.23 | $72.94 | -74% |
| EV/Sales vs peers, growth & margin adjusted | $34.26 | $47.89 | $67.24 | -74% |
| Residual income | $0.56 | $0.61 | $0.66 | -100% |
| Analysts' price targets | $225.00 | $242.46 | $270.00 | +34% |
| Path-to-margin DCF | $25.41 | $40.56 | $55.63 | -78% |
| Path-to-margin DCF, dilution-adjusted | $24.90 | $40.00 | $55.04 | -78% |
| Exit-multiple (venture) method | $51.38 | $84.53 | $128.66 | -53% |
| EV/Sales vs Rule of 40 (all-company fit) | $11.26 | $27.62 | $72.51 | -85% |
| Survival-weighted value | $17.13 | $25.87 | $34.58 | -86% |
Glaukos' latest quarter
Glaukos, Q3 2026: revenue $211M (+58% year over year), operating margin 0.4%, net earnings $2.0M, operating cash flow $38.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for GKOS stock?
The median of 13 analysts' 12-month targets is $241.00, +33% from $181.43; the range is $225.00 to $270.00. The average rating is strong buy.
What is Glaukos' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $0.61 and $242.46, with a middle value of $40.00 against a price of $181.43. Each method's assumptions are on the page.
Does Glaukos usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is GKOS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.